Medical Condition News

RSS

Cancer Research UK offers translation service for people affected by cancer

Thanks to a partnership with Language Line - who interpret telephone conversations in over 170 languages - people affected by cancer who need an interpreter can now have their questions answered.

21 Jan 2010

FDA approves continuous-flow heart-assist device pioneered at Texas Heart Institute at SLEH

The federal Food and Drug Administration today approved a continuous-flow heart-assist device pioneered at the Texas Heart Institute (THI) at St. Luke’s Episcopal Hospital (SLEH) for use as a permanent treatment for advanced heart failure.

21 Jan 2010

Scientific/technical review for XIAFLEX' European MAA commences

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.

21 Jan 2010

Five questions for successful weight loss

The American Society of Bariatric Physicians (ASBP) works with physicians so they’re better prepared to deal with society’s obesity epidemic. Even though people focus on weight loss more in January than any other month, successful weight loss is a year-round long-term initiative that goes far beyond just diet and exercise. The ASBP has highlighted five questions everyone who needs to lose weight should ask their physician.

21 Jan 2010

University of Miami psychologists use non-expert student observers in autism research

Non-expert is not often a term that one would associate with scientific research, but it could become a new trend in psychology research. Some recent studies have begun to rely on non-expert students to observe and provide data during experiments.

21 Jan 2010

Data demonstrates overall radiation with digital mammography is less than film mammography

Data from one of the largest mammography trials in history demonstrates that overall the radiation dose associated with digital mammography is significantly lower (averaging 22 percent lower) than that of conventional film mammography and that the reduction could be greater in women with larger and denser breasts, according to a study published in the February issue of the American Journal of Roentgenology.

21 Jan 2010

US FDA grants tentative approval for LPI's Memantine HCl tablets

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received tentative approval from the US Food and Drug Administration (US FDA) for its Memantine Hydrochloride tablets, 5mg and 10mg.

21 Jan 2010

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

IsoRay, Inc., announced today that on October 10, 2009, Dr. Bhupesh Parashar, Dr. A Gabriella Wernicke and Dr. KS Clifford Chao from the Department of Radiation Oncology, and Dr. Jeffery Milsom from the Department of Gastrointestinal Surgery, at Weill Cornell Medical Center performed the world’s first Cesium-131(Cs-131) implant for the treatment of colorectal cancer.

21 Jan 2010

MDRNA to receive European patent for its intranasal insulin formulation

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the European Patent Office intends to grant a patent for application EP06826368 covering formulations for the intranasal delivery of rapid acting insulin, and its use for the treatment of diabetes.

21 Jan 2010

CPRIT awards the first $61M in grants for cancer research

The Cancer Prevention and Research Institute of Texas (CPRIT) awarded on January 20th the first $61 million in grants for cancer research projects at academic institutions and private companies throughout Texas. These are the inaugural grants of the $3 billion to be invested in cancer research in Texas over the next ten years.

21 Jan 2010

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Amgen today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix® (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME '203' and '181' trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010.

21 Jan 2010

Genomic Health announces global commercial availability of its Oncotype DX colon cancer test

Genomic Health, Inc. today announced worldwide commercial availability of its Oncotype DX® colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. The 12-gene advanced diagnostic test is clinically validated to predict individual recurrence risk in stage II colon cancer patients following surgery, as reported at the 2009 American Society of Clinical Oncology (ASCO) meeting.

21 Jan 2010

China Pharma Holdings announces completion of clinical trials for Candesartan

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that the Company has completed clinical trials for Candesartan, an anti-hypertension drug, and submitted the generic drug production application to the SFDA.

21 Jan 2010

Neuralstem announces treatment of first ALS patient with spinal cord stem cells

Neuralstem, Inc. announced that the first ALS patient was treated with its spinal cord stem cells yesterday at the Emory ALS Center at Emory University, in Atlanta, GA. A total of up to 18 patients is planned to be treated in this first U.S. clinical trial to evaluate human neural stem cells for the treatment of ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). ALS affects roughly 30,000 people in the U.S., with about 5,600 new diagnoses per year, according to the ALS Association.

21 Jan 2010

Enrollment complete in Vertos Medical's U.S. IRB I "mild" procedure Patient Outcomes Trial

Medical device company Vertos Medical Inc. has announced the completion of enrollment in its post-market U.S. IRB (Institutional Review Board) I Patient Outcomes Trial, a 75-patient study of the mild procedure. The open-label, single-arm, prospective, IRB-approved study is intended to gather patient outcomes data following treatment for symptomatic central canal spinal stenosis using proprietary mild devices. Results from the trial, which is being conducted by 14 investigators at academic and private practice settings across the United States, are expected to be published during 2010.

21 Jan 2010

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

BioNumerik Pharmaceuticals, Inc. today announced the treatment of the first patients in a global multi-center Phase III clinical trial of Tavocept (BNP7787) in patients with primary adenocarcinoma of the lung, the most common type of lung cancer. In previous studies, Tavocept demonstrated the potential to substantially increase overall and one year patient survival while concurrently preventing and reducing the incidence and severity of common chemotherapy side-effects as compared to other currently available treatments for advanced lung cancer.

21 Jan 2010

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

Pfizer Inc. and Auxilium Pharmaceuticals, Inc. today announced that Pfizer received notification from the European Medicines Agency that the Marketing Authorization Application (MAA) for XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, biologic for the treatment of Dupuytren’s contracture (a condition resulting in the contracture of the fingers into the palm), has completed the validation phase successfully. As a result, the scientific/technical review procedure commenced on 21 January 2010.

21 Jan 2010

Osteoporosis-related event of 2010 to be held in Florence, Italy

Don't miss the most important osteoporosis-related event of 2010, to be held in the center of Florence, Italy from May 5 to 8, 2010.

21 Jan 2010

Christiana Care Health System earns Gold Seal of Approval for Primary Stroke Centers

Christiana Care Health System has earned the Gold Seal of Approval(TM) from The Joint Commission for Primary Stroke Centers. Christiana Care earned this distinction after the Joint Commission conducted an on-site review in November 2009.

21 Jan 2010

Efficacy of neurofeedback in treating ADD/ADHD

On January 22, the Potomac Institute for Policy Studies will present a guest lecture by Don DuRousseau, founder and CEO of Human Bionics LLC, a neurotechnology company specializing in brain-computer interface (BCI) systems. Mr. DuRousseau will explore the use of neurotechnology techniques, including the increasingly popular neurofeedback, as a treatment for ADD/ADHD.

21 Jan 2010

Medical Condition News

Cancer Research UK offers translation service for people affected by cancer

FDA approves continuous-flow heart-assist device pioneered at Texas Heart Institute at SLEH

Scientific/technical review for XIAFLEX' European MAA commences

Five questions for successful weight loss

University of Miami psychologists use non-expert student observers in autism research

Data demonstrates overall radiation with digital mammography is less than film mammography

US FDA grants tentative approval for LPI's Memantine HCl tablets

World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center

MDRNA to receive European patent for its intranasal insulin formulation

CPRIT awards the first $61M in grants for cancer research

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Genomic Health announces global commercial availability of its Oncotype DX colon cancer test

China Pharma Holdings announces completion of clinical trials for Candesartan

Neuralstem announces treatment of first ALS patient with spinal cord stem cells

Enrollment complete in Vertos Medical's U.S. IRB I "mild" procedure Patient Outcomes Trial

BioNumerik Pharmaceuticals commences patient treatment in Tavocept Phase III trial

Pfizer and Auxilium Pharmaceuticals announce completion of European MAA validation phase for XIAFLEX

Osteoporosis-related event of 2010 to be held in Florence, Italy

Christiana Care Health System earns Gold Seal of Approval for Primary Stroke Centers

Efficacy of neurofeedback in treating ADD/ADHD

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Latest News